| Battelle Medical Device Solutions Press Release |  |
BATTELLE HELPS BRING NEW TECHNOLOGY TO MARKET
Medrad launches the XDS™ extravasation detector
Columbus, OH – July 16, 2007 — Battelle and MEDRAD, INC., recently announced the launch of the MEDRAD XDS™ Extravasation Detector, a technology that enhances the safety of contrast media injection through early detection of extravasations.
Seeking a partner with strong product innovation and development skills to assist in this effort, MEDRAD turned to Battelle—specifically Battelle Medical Device Solutions.
"During the course of the project, Battelle demonstrated complex problem solving abilities and drove much of the innovation in the final product," said Doug Descalzi, executive director, CT New Product Development at MEDRAD. "Their contributions were a key success factor in achieving the program's objectives."
Working closely from technology exploration through product development, MEDRAD and Battelle jointly invented the electrical permittivity technology that enables XDS™ and developed the commercial product. XDS™ continuously monitors the tissue immediately surrounding and directly beneath the injection site for changes in relative permittivity signaling fluid accumulation.
"In addition to providing the market with a long-sought solution to real-time extravasation detection through the invention of the electrical permittivity approach, the development team had to apply substantial creative energy to envision and design a novel sensor and unique detection algorithm," stated Daniel Kramer, Battelle Medical Device Solutions project manager. Kramer also noted that XDS™ provides the first practical, reliable, and economical alternative to the current method of visual observation or physical palpitation of an injection site for the detection of fluids in the surrounding tissue.
About Battelle
Battelle Medical Device Solutions delivers a comprehensive set of R&D services integrating design, engineering, and life science capabilities for medical device, biotechnology, and pharmaceutical firms serving a wide range of therapeutic and diagnostic markets. Battelle Medical Device Solutions supports customers through the complete product life cycle by offering Applied Research, Device Development, Clinical Research, and Sustaining Engineering services.
Battelle is the world's largest non-profit independent research and development organization, with 20,000 employees in more than 120 locations worldwide, including five national laboratories Battelle manages or co-manages for the U.S. Department of Energy. Headquartered in Columbus, Ohio, Battelle conducts $3.8 billion in R&D annually through contract research, laboratory management, and technology commercialization. As a non-profit charitable trust with an eye toward the future, Battelle actively supports and promotes science and math education.
For more information, visit www.battelle.org or contact Media Relations Manager Mark Berry at (614) 424-5544 or berrym@battelle.org.
About MEDRAD, Inc.
MEDRAD, INC. is a worldwide leading provider of medical devices and services that enable and enhance imaging procedures of the human body. Used in diagnostic imaging, MEDRAD's product offerings include a comprehensive line of vascular injection systems, magnetic resonance (MR) surface coils and patient care products, and equipment services. Total 2006 revenues were $478 million. MEDRAD is a 2003 recipient of the Malcolm Baldrige National Quality Award, the top honor a U.S. company can receive for quality and business excellence. The company's world headquarters is near Pittsburgh, Pennsylvania, in the United States. MEDRAD is an affiliate of Bayer AG. More company information is available at www.medrad.com.
